C07D 403/04
Directly linked by a ring-member-to-ring-member bond
Official title: directly linked by a ring-member-to-ring-member bond
C07D403/04 (Directly linked by a ring-member-to-ring-member bond) appears on 5,630 US grants and 7,070 published applications in this corpus.
Search patents in C07D- Granted patents
- 5,630
- Published applications
- 7,070
- Assignees
- 2,044
- Inventors
- 17,892
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 9 | 0 |
| 1977 | 8 | 0 |
| 1978 | 2 | 0 |
| 1979 | 1 | 0 |
| 1980 | 1 | 0 |
| 1981 | 1 | 0 |
| 1982 | 2 | 0 |
| 1983 | 2 | 0 |
| 1984 | 10 | 0 |
| 1985 | 17 | 0 |
| 1986 | 28 | 0 |
| 1987 | 30 | 0 |
| 1988 | 28 | 0 |
| 1989 | 40 | 0 |
| 1990 | 27 | 0 |
| 1991 | 31 | 0 |
| 1992 | 43 | 0 |
| 1993 | 39 | 0 |
| 1994 | 36 | 0 |
| 1995 | 45 | 0 |
| 1996 | 62 | 0 |
| 1997 | 79 | 0 |
| 1998 | 66 | 0 |
| 1999 | 64 | 0 |
| 2000 | 50 | 0 |
| 2001 | 62 | 14 |
| 2002 | 89 | 70 |
| 2003 | 87 | 143 |
| 2004 | 73 | 234 |
| 2005 | 75 | 212 |
| 2006 | 110 | 188 |
| 2007 | 142 | 253 |
| 2008 | 111 | 266 |
| 2009 | 144 | 264 |
| 2010 | 195 | 294 |
| 2011 | 161 | 296 |
| 2012 | 230 | 273 |
| 2013 | 267 | 302 |
| 2014 | 272 | 310 |
| 2015 | 296 | 340 |
| 2016 | 237 | 357 |
| 2017 | 313 | 376 |
| 2018 | 289 | 331 |
| 2019 | 289 | 351 |
| 2020 | 282 | 381 |
| 2021 | 243 | 343 |
| 2022 | 216 | 323 |
| 2023 | 194 | 379 |
| 2024 | 193 | 312 |
| 2025 | 206 | 286 |
| 2026 | 133 | 172 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- PHD inhibitor compounds, compositions, and use6 Oct 2026US 12,753,161 B2Akebia Therapeutics, Inc.
- Aminopyrimidine compounds6 Oct 2026US 12,753,165 B2Tyra Biosciences, Inc.
- 1,5-disubstituted 1,2,3-triazoles are inhibitors of RAC/CDC42 GTPases6 Oct 2026US 12,753,183 B2University of Puerto Rico
- NAMPT modulators29 Sep 2026US 12,747,203 B2Cytokinetics, Inc.
- TEAD inhibitors29 Sep 2026US 12,747,207 B2Orion Corporation
- Cis-8-(3,5-Difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]decan-2-one derivatives8 Oct 2026US 2026/0308140 A1Gruenenthal GmbH
- Cdk2 inhibitors and methods of using same8 Oct 2026US 2026/0308145 A1Guangdong Touchstone Translational Research Institute Co., Ltd.
- Heterocyclic inhibitors of rho gtpases for the treatment of disease8 Oct 2026US 2026/0308180 A1
- Aromatic substituent-containing (hetero) aryl-imidazole compound, and preparation method therefor and use thereof1 Oct 2026US 2026/0297065 A1Open Source Therapeutics
- Compounds for treating cancer1 Oct 2026US 2026/0297066 A1Genesis Molecular AI, Inc.
Most cited
By later US patents
- Pyrimidine derivatives and processes for the preparation thereof595US 5,521,184 ACiba-Geigy Corporation · 1996
- P38 inhibitors and methods of use thereof444US 7,799,782 B2Array BioPharma Inc. · 2010
- Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof277US 5,549,974 AAffymax Technologies N.V. · 1996
- Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases232US 6,180,632 B2Aventis Pharmaceuticals Products Inc. · 2001
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase226US 5,480,883 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1996